Jee-Young Lee, Hyeo-Il Ma, Joaquim J Ferreira, José-Francisco Rocha, Young Hee Sung, In-Uk Song, Tae-Beom Ahn, Do Young Kwon, Sang-Myung Cheon, Jong-Min Kim, Chong Sik Lee, Phil Hyu Lee, Jeong-Ho Park, Jae-Hyeok Lee, Mee Young Park, Sang Jin Kim, Jong Sam Baik, Seong-Min Choi, Hae-Won Shin, Ho-Won Lee, Suk Yun Kang, Beomseok Jeon
BACKGROUND: Increasing levodopa (L-dopa)/dopa decarboxylase inhibitor (DDCI) daily dose or adding a catechol-O-methyltransferase (COMT) inhibitor to levodopa/DDCI therapy are strategies used to manage wearing-off symptoms in Parkinson's disease (PD) patients. OBJECTIVES: To evaluate the COMT inhibitor opicapone versus an additional dose of levodopa to treat early wearing-off in PD patients. METHODS: ADOPTION was a randomized, parallel-group, open-label, Phase 4 study conducted in Korea...
April 9, 2024: Movement Disorders Clinical Practice